Bupropion as the treatment of choice in depression associated with Parkinson’s disease and it’s various treatments

Raskin, Sergey; Durst, Rimona

doi:10.1016/j.mehy.2010.07.024

Cited by 39 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Success with bupropion has been described in case reports only [111]. However, the unique dual norepinephrine and dopamine reuptake inhibitory action of bupropion, without the potential serotoninergic side effects (weight gain, sedation, sexual dysfunction) seen in SSRIs, SNRIs, and TCAs, may make it ideally suited to treat depressive symptoms in PD [112]. The NRI atomoxetine was evaluated in a blinded RCT, and there was no improvement in depression [18].…”

Section: Pharmacologic Management Of Depressionmentioning

confidence: 99%

Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease

Connolly

Fox

2014

Neurotherapeutics

View full text Add to dashboard Cite

Neuropsychiatric symptoms are common in Parkinson's disease (PD) and add significantly to the burden of disease. These symptoms are most commonly part of the disease spectrum owing to pathological changes within relevant brain regions. Neuropsychiatric problems include disorders of cognition, ranging from mild cognitive impairment to dementia, psychotic symptoms, including, most commonly, well-formed visual hallucinations and paranoid delusions, and mood disorders, such as depression and anxiety. The other common cause of neuropsychiatric problem is secondary to use of dopaminergic drugs. Some PD patients may develop behavioral disorders, including impulse control disorders (ICDs) and addictive symptoms. Psychosis can be due to a mixture of underlying pathology, with triggering or worsening of symptoms with changes to PD medications. Currently, management of these disorders primarily uses therapies developed for general psychiatry and cognitive neurology, rather than specifically for PD. However, significant adverse effects, such as worsening of the motor symptoms of PD, can limit use of some drug therapies. Identification of drug-induced symptoms, such as ICDs, enables withdrawal of the offending drug as the principal management strategy. Research is ongoing in an effort to develop more specific therapies for PD-related neuropsychiatric symptoms.

show abstract

Section: Pharmacologic Management Of Depressionmentioning

confidence: 99%

Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease

Connolly

Fox

2014

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Nonetheless, clinical practice has brought an overall positive experience with these drugs. Bupropion, that inhibits the reuptake of dopamine and noradrenaline, has been suggested by some to have a role in the treatment of depression in PD (Raskin and Durst, 2010; Zaluska and Dyduch, 2011), but controlled trials are also lacking. In any case, it appears that sedation and sexual dysfunction are lower with bupropion, when compared to SSRIs (Labbate et al, 2009).…”

Section: Management Of Pd-d: General Principlesmentioning

confidence: 99%

Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management

Meireles¹,

Massano²

2012

Front. Neur.

137

104

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a common, disabling, neurodegenerative disorder. In addition to classical motor symptoms, non-motor features are now widely accepted as part of the clinical picture, and cognitive decline is a very important aspect of the disease, as it brings an additional significant burden for the patient and caregivers. The diagnosis of cognitive decline in PD, namely mild cognitive impairment (MCI) and dementia, can be extremely challenging, remaining largely based on clinical and cognitive assessments. Diagnostic criteria and methods for PD dementia and MCI have been recently issued by expert work groups. This manuscript has synthesized relevant data in order to obtain a pragmatic and updated review regarding cognitive decline in PD, from milder stages to dementia. This text will summarize clinical features, diagnostic methodology, and therapeutic issues of clinical decline in PD. Relevant clinical genetic issues, including recent advances, will also be approached.

show abstract

“…(1) Bupropion Dopamine agonists have been considered as antidepressants in some studies, but they may cause side effects such as confusion, somnolence and dizziness, so the role of dopamine agonist in depressive PD still needs to be explored [20]. While Bupropion, as a dopaminergic and noradrenergic anti-depressant, could be a possible treatment for depressive symptoms associated with PD, without serotonin related side effects.…”

Section: Antidepressantsmentioning

confidence: 99%

Drug Repositioning for Parkinson�s Disease Based on Adverse Drug Reactions Detected from Social Media (Preprint)

Zhao¹,

Yang²

2017

Preprint

View full text Add to dashboard Cite

show abstract

Bupropion as the treatment of choice in depression associated with Parkinson’s disease and it’s various treatments

Cited by 39 publications

References 28 publications

Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease

Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson's Disease

Cognitive Impairment and Dementia in Parkinson’s Disease: Clinical Features, Diagnosis, and Management

Drug Repositioning for Parkinson�s Disease Based on Adverse Drug Reactions Detected from Social Media (Preprint)

Contact Info

Product

Resources

About